No evidence of gemcitabine accumulation during weekly administration

[1]  S. Cascinu,et al.  Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients. , 2002, Anticancer research.

[2]  G. Peters,et al.  Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) , 2002 .

[3]  Helen Brown,et al.  Applied Mixed Models in Medicine , 2000, Technometrics.

[4]  G. Peters,et al.  Gemcitabine-cisplatin: a schedule finding study. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  G. Peters,et al.  Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Peters,et al.  Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Ratain,et al.  Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  G. Peters,et al.  Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. , 1998, Seminars in oncology.

[9]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Peters,et al.  Gemcitabine: Future Prospects of Single-Agent and Combination Studies. , 1997, The oncologist.

[11]  S. Allerheiligen,et al.  Preclinical, pharmacologic, and phase I studies of gemcitabine. , 1997, Seminars in oncology.

[12]  W. Plunkett,et al.  Gemcitabine: preclinical pharmacology and mechanisms of action. , 1996, Seminars in oncology.

[13]  G. Peters,et al.  Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. , 1994, Biochemical pharmacology.

[14]  G. Peters,et al.  2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. , 1993, Biochemical pharmacology.

[15]  W. Plunkett,et al.  A quantitative assay for fragmented DNA in apoptotic cells. , 1992, Analytical biochemistry.

[16]  H. Kantarjian,et al.  Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Kantarjian,et al.  Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. , 1990, Cancer research.

[18]  M. Namer,et al.  Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation. , 1985, British Journal of Cancer.

[19]  E. Casper,et al.  Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas , 2004, Investigational New Drugs.

[20]  G. Peters,et al.  Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. , 2002, European journal of cancer.

[21]  G. Peters,et al.  Similar Changes Were Induced by Cladribine and by Gemcitabine, in the Deoxypyrimidine Salvage, During Short Term Treatments , 1998 .